News Search

17 Mar 2015 | Other

Actavis Completes Allergan Acquisition

Actavis plc (NYSE: ACT) today announced that it has completed the acquisition of Allergan, Inc. (NYSE: AGN) in a cash and equity transaction valued at approximately $70.5 billion. The combination creates one of the world’s top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23 billion anticipated in 2015.

"The combination of Actavis and Allergan creates an exceptional global pharmaceutical company and a leader in a new industry model – Growth Pharma," said Brent Saunders, CEO and President of Actavis. "Anchored by world-renowned brand franchises, a leading global generics business, a premier pharmaceutical development pipeline and an experienced management team committed to maintaining highly efficient operations across the organization, we are creating an unrivaled foundation for long-term growth."

Full story on Allergan.com
Media Contacts
Mark Marmur
Global Corporate Media Relations
Tel: +1 (862) 261 7558
Fran DeSena
U.S. Product Media Relations
Tel: +1 (201) 427-8762

Karina Calzadilla
Investor Relations
Tel: +1 862 261 7488